Trials / Completed
CompletedNCT01994629
Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 12 Months – 15 Months
- Healthy volunteers
- Accepted
Summary
Evaluate the immune response and reactogenicity of one dose of Meningococcal ACWY-cross reactive material (CRM) and Meningococcal ACWY-tetanus toxoid (TT) in 12-15 months old healthy toddlers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MenACWY-CRM | MenACWY-CRM |
| BIOLOGICAL | MenACWY-TT | MenACWY-TT |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2014-04-01
- Completion
- 2014-10-01
- First posted
- 2013-11-26
- Last updated
- 2015-11-04
- Results posted
- 2015-11-04
Locations
4 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01994629. Inclusion in this directory is not an endorsement.